Wegovy’s retail list price is roughly $1,350 per month, but almost nobody pays that. Your actual out-of-pocket cost depends on whether you use the injectable pens or the newer oral tablets, whether you have insurance, and which discount programs you use. Most people paying cash end up spending between $149 and $399 per month.
Retail Price vs. What You’ll Actually Pay
The average retail price for a monthly supply of Wegovy at U.S. pharmacies hovers around $1,600 to $1,650, regardless of the dose strength. That number appears on pharmacy shelves for both the injectable pens and the oral tablets. But this sticker price is largely fictional. It exists as a starting point for negotiations between the manufacturer, Novo Nordisk, and insurance companies or pharmacy benefit managers.
In practice, Novo Nordisk has introduced direct-to-consumer pricing that drops the cost dramatically. For the injectable pens, the self-pay price runs about $199 to $399 per month depending on your dose. The oral tablets (a newer option taken daily instead of injected weekly) cost $149 to $299 per month at cash-pay pricing through select pharmacies and telehealth providers. The lowest doses tend to sit at the bottom of that range, while the full maintenance doses cost more.
How Pricing Changes as Your Dose Increases
Wegovy treatment starts at a low dose and gradually increases over several months. The starting dose for the injectable pen (0.25 mg) currently has a limited-time introductory price of $199 for a two-month supply for new patients, reverting to $349 per box after June 2026. At the full maintenance dose of 2.4 mg, you’ll pay $349 per month.
For the tablets, the lower strengths (1.5 mg and 4 mg) run $149 per month, while the 9 mg dose jumps to $299. The highest tablet dose, 25 mg, doesn’t yet have the same discounted pricing and can cost over $1,300 even through discount programs.
Novo Nordisk also offers subscription-style plans that reduce the per-month cost if you commit to a longer period. A 12-month plan brings the injectable price down to about $249 per month, while a 3-month plan runs $329. If you know you’ll be on the medication long-term (and most people are, since weight tends to return after stopping), the annual plan offers real savings.
What Insurance Typically Covers
Private insurance coverage for Wegovy varies widely. Many employer-sponsored plans and commercial insurers do cover it, but almost all require prior authorization. That means your doctor needs to submit documentation proving you meet specific criteria before the insurer will approve the prescription. The typical requirements include a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like high blood pressure, type 2 diabetes, or high cholesterol. Some plans also require evidence that you’ve tried diet and exercise programs first.
If your insurer does cover Wegovy, your copay could range from $0 to $100 or more per month depending on your plan’s formulary tier and deductible structure. But plenty of commercial plans still exclude weight-loss medications entirely, leaving you responsible for the full cost.
Medicare Coverage Is Limited but Expanding
Medicare’s relationship with Wegovy is complicated. Currently, Medicare Part D can cover Wegovy only when it’s prescribed specifically to reduce cardiovascular risk in adults who already have established heart disease (prior heart attack, stroke, or peripheral artery disease) and are also overweight or obese. If your doctor prescribes it purely for weight loss, Part D won’t pay for it under existing rules.
That’s set to change partially in mid-2026. CMS is launching a temporary program called the Medicare GLP-1 Bridge, running from July 2026 through December 2027, which will give eligible Medicare beneficiaries access to Wegovy for weight reduction specifically. The details of cost-sharing under this bridge program are still being finalized, but it represents the first time Medicare will cover Wegovy for weight loss rather than only for cardiovascular protection.
Patient Assistance for Lower-Income Households
Novo Nordisk runs a Patient Assistance Program (PAP) that provides Wegovy at no cost to qualifying patients. To be eligible, you need to be a U.S. citizen or legal resident with a household income at or below 400% of the federal poverty level. For a single person in 2025, that’s roughly $60,000 per year. You must also either have Medicare or be completely uninsured. If you carry private or commercial insurance, you don’t qualify, even if your plan doesn’t cover Wegovy.
There are additional hoops. Uninsured patients need to provide proof they were denied Medicaid before enrolling. Medicare beneficiaries earning below 150% of the federal poverty level must show they were denied the Part D Extra Help program. The application process requires documentation, but for people who qualify, it eliminates the cost entirely.
Telehealth and Pharmacy Discount Options
Several telehealth platforms now offer Wegovy prescriptions bundled with virtual medical visits. Ro, for example, lists the oral Wegovy tablets at $149 to $299 per month as a cash price, though the cost of their membership program is separate from the medication price. Other platforms like WeightWatchers Clinic, Hims, and Found offer similar arrangements with varying visit fees on top of the drug cost.
Pharmacy discount cards can also help. GoodRx lists coupon prices as low as $149 for the lower-dose tablets and $199 for the starter-dose injectable pens. However, the discounted prices aren’t uniform across all doses. Some mid-range doses for both the pens and tablets still price above $1,300 even with coupons, so it’s worth checking the specific dose you’ve been prescribed rather than assuming the advertised low price applies to your situation.
Compounded Semaglutide as a Cheaper Alternative
Some people turn to compounded semaglutide, which contains the same active ingredient as Wegovy but is mixed by compounding pharmacies rather than manufactured by Novo Nordisk. These versions typically cost $200 to $500 per month. They’re available through many telehealth providers and don’t require insurance.
The trade-off is regulatory oversight. Compounded medications aren’t FDA-approved, and quality can vary between pharmacies. The FDA has raised safety concerns about some compounded semaglutide products, and Novo Nordisk has actively pushed back against them. Compounded versions also lack the pre-filled dosing convenience of Wegovy’s pen system, often requiring you to draw doses from a vial. For people who can’t access or afford brand-name Wegovy, compounded semaglutide remains a common workaround, but it comes with caveats worth understanding before you commit.
Realistic Monthly Budget by Situation
- With good commercial insurance: $0 to $100 per month, assuming your plan covers Wegovy and you meet prior authorization criteria.
- Cash pay with Novo Nordisk pricing: $149 to $399 per month depending on dose and whether you choose the tablet or injection.
- Subscription plan (injection): $249 per month on a 12-month commitment, $329 on a 3-month plan.
- Patient Assistance Program: $0, if your income qualifies and you have Medicare or no insurance.
- Compounded semaglutide: $200 to $500 per month through telehealth or compounding pharmacies.
- Full retail without any discounts: roughly $1,350 to $1,650 per month, though very few people pay this.
The cost landscape for Wegovy has shifted significantly since its launch, when nearly everyone without insurance faced the full list price. Between Novo Nordisk’s direct pricing, the new oral tablet option, and expanding Medicare access in 2026, the realistic out-of-pocket cost for most people now falls in the $150 to $400 range per month.